SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-468640"
 

Search: onr:"swepub:oai:DiVA.org:uu-468640" > Long-term tolerabil...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Flygt, HjalmarUppsala universitet,Hematologi (author)

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-08-31
  • John Wiley & Sons,2021
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-468640
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-468640URI
  • https://doi.org/10.1111/ejh.13699DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147513672URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Title in Web of Science: Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
  • ObjectivesTreatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-α in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-α (PegIFN-α) in combination with dasatinib (DAS) in CML-CP.MethodsForty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 μg/wk of PegIFN-α was added and increased to 25 μg/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data.ResultsAfter 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study.ConclusionInitial addition of PegIFN-α to DAS shows good long-term efficacy without increased toxicity.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Söderlund, StinaUppsala universitet,Hematologi(Swepub:uu)stiso746 (author)
  • Stentoft, JesperAarhus Univ Hosp, Dept Hematol, Aarhus, Denmark. (author)
  • Richter, JohanSkane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden. (author)
  • Koskenvesa, PerttuUniv Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland. (author)
  • Mustjoki, SatuUniv Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland.;Univ Helsinki, Dept Clin Chem & Hematol, Helsinki, Finland. (author)
  • Majeed, WaleedStavanger Univ Hosp, Dept Hematooncol, Stavanger, Norway. (author)
  • Lübking, AnnaSkane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden. (author)
  • Dreimane, ArtaLinköping Univ Hosp, Dept Hematol, Linköping, Sweden. (author)
  • Markevärn, BeritUmeå Univ Hosp, Dept Hematol, Umeå, Sweden. (author)
  • Stenke, LeifKarolinska Institutet (author)
  • Myhr Eriksson, KristinaSunderby Hosp, Dept Internal Med & Hematol, Luleå, Sweden. (author)
  • Gjertsen, Bjørn ToreHaukeland Hosp, Hematol Sect, Dept Internal Med, Bergen, Norway. (author)
  • Gedde-Dahl, TobiasNatl Hosp Norway, Oslo Univ Hosp, Dept Hematol, Oslo, Norway. (author)
  • Dimitrijevic, AndrejaOdense Univ Hosp, Dept Hematol, Odense, Denmark. (author)
  • Udby, LeneZealand Univ Hosp, Dept Hematol, Roskilde, Denmark. (author)
  • Olsson-Strömberg, UllaUppsala universitet,Hematologi(Swepub:uu)ulols170 (author)
  • Hjorth-Hansen, HenrikSt Olavs Hosp Trondheim, Dept Hematol, Trondheim, Norway.;Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway. (author)
  • Uppsala universitetHematologi (creator_code:org_t)

Related titles

  • In:European Journal of Haematology: John Wiley & Sons107:6, s. 617-6230902-44411600-0609

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view